

**Montana Healthcare Programs Drug Utilization Review Board Agenda**  
**Hosted by Mountain Pacific Quality Health**  
**June 18, 2025**  
**1-5 PM**  
**Virtual Call Only**

Register in advance for this meeting:

<https://events.teams.microsoft.com/event/a473272b-599b-4010-b2a5-0d191c0e106e@1f053f7a-e47d-43fd-9182-8507c9ff10c7> [events.teams.microsoft.com]

1. Introductions

2. Public Comment- 15 minutes.

All persons wishing to speak through the video conferencing platform must notify the Department by submitting their name and topic they wish to speak on via <https://forms.office.com/g/EkPyKbJYTv> by **noon** the day prior to the meeting. Individual comment will be limited to a maximum of 3 minutes per person and is subject to further limitations depending on the number of speakers (15 minutes divided by total speakers).

Due to time constraints, all persons are encouraged to provide written comment, especially those providing clinical information, to allow the board adequate time to review and research. Please email written comments and/or clinical information, with a statement indicating that it is public comment, to [PDL@mt.gov](mailto:PDL@mt.gov) at least 7 days prior to the meeting. Please limit clinical information to 2 pages and to new information since last review. New peer-reviewed randomized comparative controlled trials or randomized controlled trials with true health outcomes are most helpful. Please do not provide any pricing information.

- Meeting Minutes
  - May PDL meeting minutes

3. Department Update

4. PA Criteria updates:

- Criteria changes/dosing & age updates
  - Odactra® age expansion
  - Spravato® indication change and criteria update
  - Sublocade® dosing change and criteria update
  - Valtoco® age expansion
  - Yorvipath® criteria update
- New Indication/Formulation
  - Dupixent® new indication
  - Fasenra® new indication
  - Omvoh® new indication
  - Palforzia® new indication
  - Rinvoq® new indication

- Tremfya® new indication

5. New Drugs

- Alyftrek®
- Journavx®
- Spevigo®

6. PA Criteria removal or changes

- Xarelto® 2.5mg criteria removal

7. Mounjaro Discussion (if time permits)